Creative Medical Technology Holdings Inc

NASDAQ CELZ

Data sourced from iex and EODHD
Download Data

Creative Medical Technology Holdings Inc Current Liabilities Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -77.54%

Creative Medical Technology Holdings Inc Current Liabilities Ratio 2 year CAGR is -77.54% for the Trailing 12 Months (TTM) ending March 31, 2024, a 17.97% change year over year. The current liabilities ratio measures the proportion of a company's current liabilities in relation to its total assets. It is calculated by dividing current liabilities by total assets. This ratio indicates the percentage of a company's total assets that are financed by current liabilities, such as accounts payable and short-term debt. It helps assess the company's short-term solvency and its ability to meet immediate obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Creative Medical Technology Holdings Inc Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.06, a -92.74% change year over year.
  • Creative Medical Technology Holdings Inc Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.81, a -95.88% change year over year.
  • Creative Medical Technology Holdings Inc Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 19.57, a 48.92% change year over year.
  • Creative Medical Technology Holdings Inc Current Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 13.14, a -33.75% change year over year.
NASDAQ: CELZ

Creative Medical Technology Holdings Inc

CEO Mr. Timothy Warbington
IPO Date Nov. 6, 2015
Location United States
Headquarters 211 East Osborn Road, Phoenix, AZ, United States, 85012
Employees 4
Sector Healthcare
Industry Biotechnology
Description

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

StockViz Staff

September 20, 2024

Any question? Send us an email